SGLT-2 Inhibitors Provide CV Benefits for All Type 2 Diabetics: Analysis

Cardiovascular benefits in patients with type 2 diabetes from the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors extend to all patient subgroups, according to results of a large meta-analysis published in the Journal of the American Heart Association. The researchers included four large-scale clinical trials in the analysis. Each study looked at patients with diabetes … Continue reading SGLT-2 Inhibitors Provide CV Benefits for All Type 2 Diabetics: Analysis